The demise of Bristol-Myers Squibb Co.'s hepatitis C drug BMS-986094, which BMS discontinued development of after patients in its Phase IIb study experienced heart and kidney toxicity, stretched further than just the big pharma. The FDA put a partial clinical hold on Idenix Pharmaceuticals Inc.'s related nuc IDX184 and then slapped a hold on its next-generation nuc, IDX19368, as well.